Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer
Basel, Switzerland, April 19, 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss
biotech company developing novel T-cell receptor (TCR)-based therapeutics, today
announces the appointment of Dr. Lars Nieba as Chief Executive Officer. Dr. Søren Mouritsen,
co-founder and previous CEO, steps down in a planned transition.
Dr. Lars Nieba brings more than 25 years of experience in biopharmaceutical leadership in
R&D, business and clinical development, venture capital, manufacturing and product strategy
and has been CEO and a Scientific Advisor to a number of biotechnology companies. Dr.
Nieba has held previous positions in big pharma and VC firms including Roche, Bayer and
Pureos Bioventures where he touched a wide variety of modalities in drug development, from
small molecules, through to therapeutic proteins, antibodies and gene therapies.